Related Experiment Video
Updated: Aug 16, 2026
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Antiplatelet and anticoagulation for patients with prosthetic heart valves
1Division of Cardiology, Department of Medicine, London Health Sciences Centre, University of Western Ontario, 375 South Street, London, Ontario, Canada, N6A 4G5.
Insights
Adding antiplatelet therapy to oral anticoagulation for prosthetic heart valves significantly reduces thromboembolic events and mortality. However, this combination increases the risk of major bleeding, necessitating careful patient selection and monitoring.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Patients with prosthetic heart valves face elevated risks of valve thrombosis and arterial thromboembolism.
- Standard management involves oral anticoagulation, with antiplatelet agents sometimes added to mitigate these risks.
- The efficacy and safety of combining antiplatelet therapy with oral anticoagulation require thorough evaluation.
Purpose of the Study:
- To compare the effectiveness and safety of adding antiplatelet therapy to standard oral anticoagulation in patients with prosthetic heart valves.
- To synthesize evidence from randomized controlled trials on this therapeutic strategy.
Main Methods:
- A systematic search of major databases (Cochrane Central Register, MEDLINE, EMBASE) was conducted.
- Randomized controlled trials comparing oral anticoagulation alone versus oral anticoagulation plus antiplatelet therapy were included.
- Data on thromboembolic events, mortality, and bleeding were extracted and analyzed.
Main Results:
- Eleven studies involving 2,428 patients were analyzed.
- The addition of antiplatelet agents significantly reduced thromboembolic events (OR 0.39) and total mortality (OR 0.55).
- Major bleeding risk increased with the addition of antiplatelet therapy (OR 1.66).
Conclusions:
- Combining antiplatelet therapy (dipyridamole or low-dose aspirin) with oral anticoagulation lowers systemic embolism and death risk in prosthetic heart valve patients.
- This combined approach elevates the risk of major bleeding.
- Effectiveness and safety appear comparable between low-dose aspirin and dipyridamole.
Background:
Patients with prosthetic heart valves are at increased risk for valve thrombosis and arterial thromboembolism. Oral anticoagulation alone, or the addition of antiplatelet drugs, has been used to minimize this risk. An important issue is the effectiveness and safety of the latter strategy.
Objectives:
To compare the effectiveness and safety of adding antiplatelet therapy to standard oral anticoagulation among patients with prosthetic heart valves.
Search Strategy:
We searched the Cochrane Central Register of Controlled Trials (Cochrane Library Issue 2, 2003), MEDLINE (January 1966 to August 2002), EMBASE (January 1988 to July 2001) and reference lists of individual reports, review articles, meta-analyses, and consensus statements.
Selection Criteria:
All reports of randomised controlled trials comparing standard dose oral anticoagulation to standard dose oral anticoagulation and antiplatelet therapy in patients with one or more prosthetic heart valves. We included reports published in any language or in abstract form.
Data Collection And Analysis:
Two reviewers independently performed the search strategy, assessed trials for inclusion criteria, study quality, and extracted data. Adverse effects information was collected from the trials.
Main Results:
Eleven studies involving 2,428 subjects met the inclusion criteria. Year of publication ranged from 1971 to 2000. Compared with anticoagulation alone, the addition of an antiplatelet agent reduced the risk of thromboembolic events (odds ratio 0.39 (95% confidence interval 0.28 to 0.56; p<0.00001)) and total mortality (odds ratio 0.55 (95% confidence interval 0.40 to 0.77; p=0.0003)). Aspirin and dipyridamole reduced these events similarly. The risk of major bleeding was increased when antiplatelet agents were added to oral anticoagulants (odds ratio 1.66 (95% confidence interval 1.18 to 2.34; p=0.003)). For major bleeding, there was no evidence of heterogeneity between aspirin and dipyridamole and in the comparison of trials performed before and after 1990, around the time when anticoagulation standardization with the international normalized ratio was being implemented.
Reviewer'S Conclusions:
Adding antiplatelet therapy, either dipyridamole or low-dose aspirin, to oral anticoagulation decreases the risk of systemic embolism or death among patients with prosthetic heart valves. The risk of major bleeding is increased with antiplatelet therapy. These results apply to patients with mechanical prosthetic valves or those with biological valves and indicators of high risk such as atrial fibrillation or prior thromboembolic events. The effectiveness and safety of low dose aspirin (100 mg daily) appears to be similar to higher dose aspirin and dipyridamole.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:27Coronary Artery Disease V: Interprofessional Care
01:27Peripheral Artery Disease III: Interprofessional Care
01:29Venous Thrombosis III: Interprofessional Care